Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12777041 | 1.00 | ADRB3 (0.39) | ADRB3ADRA2BADRA2CNPC1GMNN | |
| SCHEMBL16512401 | 0.89 | ADRB3 (0.38) | ADRB3ADRA2BADRA2C | |
| SCHEMBL11975703 | 0.88 | ADRB3 (0.34) | ADRB3ADRA2BADRA2CNPC1GMNN | |
| SCHEMBL12730861 | 0.88 | ADRB3 (0.34) | ADRB3ADRA2BADRA2CNPC1GMNN | |
| SCHEMBL11975943 | 0.85 | ADRB3 (0.35) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12730368 | 0.85 | CTSB (0.33) | ADRB3ADRA2BADRA2C | |
| SCHEMBL2158325 | 0.84 | ADRB3 (0.34) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12731025 | 0.84 | CYP3A4 (0.41) | ADRB3ADRA2BADRA2C | |
| SCHEMBL7873466 | 0.84 | ADRB3 (0.40) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12618532 | 0.83 | ADRB3 (0.52) | ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | ADRB3 4633/4885ADRA2B 4556/4885ADRA2C 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.